home / stock / imv:cc / imv:cc news

IMV:CC News and Press, Imv Inc. From 02/13/23

Stock Information
Company Name: Imv Inc.
Stock Symbol: IMV:CC
Market: TSXC
Website: imv-inc.com
Menu
IMV:CC IMV:CC Quote IMV:CC Short IMV:CC News IMV:CC Articles IMV:CC Message Board
Get IMV:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
IMV:CC - IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial

Early analysis reveals clinically meaningful activity in refractory DLBCL patients Multiple confirmed complete responses observed in heavily pre-treated patients No adverse safety and tolerability signal reported, consistent with previous clinical trials IMV Inc. (Nasdaq...
IMV:CC - IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S

Presenting details on initial response data from the ongoing VITALIZE DLBCL trial at the Immuno-Oncology 360° conference on February 10, 2023 Expects preliminary clinical response data from the AVALON Phase 2b trial in H2 2023 Recently strengthened financial position with the...

IMV:CC - IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX ® , to potentially treat solid and hematologic cancers, announ...

IMV:CC - IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX ® , to potentially treat solid and hematologic cancers, announ...
IMV:CC - IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL

Complete responses were observed in patients who received at least three previous lines of treatment (including CAR-T's) Recent clinical data add to the growing enthusiasm for the therapeutic potential of cancer vaccines in combination with checkpoint inhibitors Oral presentation ...

IMV:CC - IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split

IMV Inc. (the “Corporation” or “IMV”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced that its common shares...

IMV:CC - IMV Shareholders Approve Reverse Stock Split at 88%

IMV’s common shares expected to begin trading on a split-adjusted basis on December 13, 2022 IMV Inc. (the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX&...
IMV:CC - IMV Receives Nasdaq Notification Regarding Market Value of Listed Securities

IMV Inc. (“ IMV ” or the “ Company ”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced that, on No...

IMV:CC - IMV Inc. Announces Third Quarter 2022 Financial and Operational Results

IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced its f...

IMV:CC - IMV Inc. to Announce Third Quarter 2022 Results and Host a Conference Call and Webcast on November 11, 2022

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Friday, November 11, 2022...
Previous 10 Next 10